p95-HER2 and trastuzumab resistance in metastatic breast cancer; is immunohistochemistry appropriate?

Kocar M., Bozkurtlar E., Telli F., Yumuk F., Kaya H., Kocar H., ...Daha Fazla

JOURNAL OF BUON, cilt.19, ss.245-249, 2014 (SCI-Expanded) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 19
  • Basım Tarihi: 2014
  • Dergi Adı: JOURNAL OF BUON
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.245-249
  • Anahtar Kelimeler: breast cancer, HER2, p95-HER2, trastuzumab, EXTRACELLULAR DOMAIN, MONOCLONAL-ANTIBODY, RECEPTOR, CLEAVAGE, P95HER2, PROTEIN, GROWTH
  • Marmara Üniversitesi Adresli: Evet

Özet

Purpose: Unraveling the mechanisms underlying the resistance to trastuzumab is important for amending the prognosis of patients with human epidermal growth factor receptor 2 (HER2) positive metastatic breast cancer. Experimentally, it has been shown that p95-HER2 positive breast tumors are resistant to trastuzumab. The aim of this study was to investigate the predictive and prognostic importance of p95-HER2 expression by immunohistochemistry in HER2-positive metastatic breast cancer patients treated with trastuzumab.